Technology Overview Sample Clauses

Technology Overview. 2 2.3.1 Genuity ATM Switches.................................................................... 2 2.3.2 Integrated Local Management Interface (ILMI)............................................ 2
Sample 1Sample 2
AutoNDA by SimpleDocs
Technology Overview. 2.3.1 Genuity ATM Switches Genuity selected the Ascend models CBX-500 & GX-550 switch as its core network ATM switches.
Sample 1Sample 2
Technology Overview. Each Counterparty doing business with Owner is required to have access to computer hardware and software that meet the requirements of the Proliance® project management software. Proliance® software and licenses to use the project database will be provided by Owner or its parent, for the duration of the Project. The hardware and software required to access this system via the Internet is to be provided by each party accessing the software. Licenses to Owner’s or its parent’s database will permit access only to this project, in accordance with permission levels configured by Owner’s or its parent’s Proliance® administrator.
Sample 1
Technology Overview. The Company’s goal is to provide SMS-based mobile entertainment to any owner of a mobile phone on the GSM networks. The Mobile Warrior technology consists of a multi-player, location based mobile role-playing game.
Sample 1
Technology Overview. Prudential’s Customer Service organization uses a standard, well-defined hardware and software suite to perform all operations in the course of satisfying Prudential’s Customer requests. This infrastructure consists of a PC for all data related activities. Workstation PCs are connected to a Local Area Network (“LAN”) segment, that is connected to a Wide Area Network (“WAN”), that is connected to Prudential’s primary and backup data processing centers.
Sample 1
Technology Overview. Autologous Engineered Skin Substitutes (ESS). Over more than 20 years, preclinical and clinical studies have resulted in development of autologous ESS. Classified as a medical devices, ESS currently consists of a lyophilized sponge of collagen and chondroitin-sulfate, populated with cultured dermal fibroblasts and epidermal keratinocytes which organize into an analog of skin tissue (Figure 1). The device develops epidermal barrier and basement membrane 13, and releases high levels of angiogenic growth factors, including but not limited to, Vascular Endothelial Growth Factor (VEGF), basic Fibroblast Growth Factor (bFGF), and Transforming Growth Factor-beta 1 (TGF-β1) 14-16. In addition, both eratinocytes and fibroblasts in culture are known to release inflammatory mediators which promote transient development of fibro-vascular tissue 17.
Sample 1
Technology Overview. VPS is a framework built in Java to measure quantifiable data across clients and servers in an architecture, operating system and application independent method on the Internet (or the Intranet). The core functionality of the system is to farm quantifiable data from multiple clients and send it to a server. The server in turn uses the data to perform required actions, such as draw graphs, send notifications, data warehouse, modify client behavior or send it to an external application. The clients and servers can be configured to exchange data between each other in real time or at some predetermined or configured intervals. The distinguishing advantage of this proprietary technology is that NO CHANGES need to be made to the existing applications to measure data across a client(s) Server(s) platform(s). The following picture is used to illustrate the logical flow of control in the VPS framework.
Sample 1
AutoNDA by SimpleDocs
Technology Overview. The technology plan creates capabilities to enable secure data exchanges for clinical and payor data as illustrated below. Clinical data will be exchanged between each of the participating practices and hospitals and the Health Information Exchange New York (HIXNY), the regional health exchange serving northern New York. HIXNY is then capable of securely sending clinical data to the clinical data warehouse (QDC). The payor data will be submitted by participating health plans, by patient, to a separate, secure payor data warehouse. Information from both the payor and EHR warehouses will ultimately be available to participating practices, and both will provide the tools necessary for practice-level continuous quality improvement as well as clinical decision support for population health management. The patient Data Warehouse will include data from the primary care providers’ EHRs augmented by the HIXNY patient record, while the Payor Data Warehouse will contain a holistic view of the patient’s experience from all the providers who have filed claims with the Adirondack Medical Home health plans for the patient. These data warehouses leverage similar web based reporting tools but utilize different, yet complementary information. Combined, these two warehouses create a more comprehensive view of the patients’ experience that neither warehouse would be able to individually provide. In addition, the three Pods were designed to enable practices to leverage the clinical decision informatics now available, including population health management and continuous quality improvement activities. Additionally, the use of the information contained in these data warehouses will facilitate the practices’ and the Pods’ ability to improve chronic disease care management, population health improvement and continuous quality improvement, utilizing the “Plan Do Study Act” (PDSA) methodology.
Sample 1

Related to Technology Overview

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Overview (a) The Employer is committed to maintaining a stable and skilled workforce, recognising its contribution to the operation of the Employer. As such, full time direct and ongoing employment is a guiding principle of this Agreement.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Information Systems Acquisition Development and Maintenance Security of System Files. To protect City Information Processing Systems and system files containing information, Service Provider will ensure that access to source code is restricted to authorized users whose specific job function necessitates such access.

  • Technology Access Fee After the Effective Date, within [***] days after receipt of the corresponding invoice from Mersana, Merck will pay to Mersana, a one-time, non-refundable, non-creditable, upfront fee of Twelve Million Dollars ($12,000,000.00) (the [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. “Technology Access Fee”). Payment of the Technology Access Fee shall be subject to any withholding Tax obligations set forth in Section 6.9.1.

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

  • Description of Consulting Services Consultant shall perform the following services pursuant to the terms of this Agreement:

Time is Money Join Law Insider Premium to draft better contracts faster.